Literature DB >> 8093856

Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells.

A S Chong1, P N Markham, H M Gebel, S D Bines, J S Coon.   

Abstract

Multidrug resistance (MDR) is the phenomenon in which cultured tumor cells selected for resistance to one chemotherapeutic agent simultaneously acquire resistance to several apparently unrelated drugs. MDR in tumor cells is associated with the over-expression of P-glycoprotein, an ATP-dependent cell-membrane transport molecule. P-glycoprotein is also expressed in several normal tissues but its physiological role(s) is unknown. We recently observed that a hierarchy of MDR-like activity exists among human peripheral blood lymphocytes in the order CD8 > CD4 > CD20 (cytotoxic/suppressor T cells, helper T cells and B cells respectively). In this study, we report that natural killer (NK) cells also express MDR-like activity. This activity could be inhibited with verapamil or solutol HS-15, two agents that reverse MDR in tumor cells. These, and four additional reversing agents, were used to investigate the possible role of P-glycoprotein in NK cells. We observed that at 10% of their IC50, five of six reversing agents inhibited NK-cell-mediated cytotoxicity; at higher (but non-toxic) doses, all six agents were inhibitory. These data suggest that NK-cell-mediated cytotoxicity may require the functional expression of an efflux molecule similar or identical to P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093856     DOI: 10.1007/bf01754414

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  26 in total

1.  Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line.

Authors:  S Yanovich; R E Hall; C Weinert
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

Review 2.  Resistance of multidrug-resistant lines to natural killer-like cell-mediated cytotoxicity.

Authors:  G Woods; L A Lund; M Naik; V Ling; A Ochi
Journal:  FASEB J       Date:  1988-09       Impact factor: 5.191

3.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

Authors:  F Thiebaut; T Tsuruo; H Hamada; M M Gottesman; I Pastan; M C Willingham
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

4.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.

Authors:  I Sugawara; I Kataoka; Y Morishita; H Hamada; T Tsuruo; S Itoyama; S Mori
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

5.  Reversal of drug-resistance in multiple myeloma with verapamil.

Authors:  B G Durie; W S Dalton
Journal:  Br J Haematol       Date:  1988-02       Impact factor: 6.998

6.  Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells.

Authors:  P M Chaudhary; I B Roninson
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

7.  Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

Authors:  W S Dalton; T M Grogan; P S Meltzer; R J Scheper; B G Durie; C W Taylor; T P Miller; S E Salmon
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

8.  Expression of a multidrug resistance gene in human cancers.

Authors:  L J Goldstein; H Galski; A Fojo; M Willingham; S L Lai; A Gazdar; R Pirker; A Green; W Crist; G M Brodeur
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

9.  Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines.

Authors:  J R Riordan; K Deuchars; N Kartner; N Alon; J Trent; V Ling
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

10.  Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.

Authors:  A T Fojo; D W Shen; L A Mickley; I Pastan; M M Gottesman
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

View more
  9 in total

Review 1.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.

Authors:  Soichi Haraguchi; Sarah K Ho; Matthew Morrow; Maureen M Goodenow; John W Sleasman
Journal:  J Leukoc Biol       Date:  2011-04-19       Impact factor: 4.962

3.  MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling.

Authors:  Toshiyuki Sakaeda; Tsutomu Nakamura; Midori Hirai; Takashi Kimura; Atsushi Wada; Tatsurou Yagami; Hironao Kobayashi; Shunji Nagata; Noboru Okamura; Takayoshi Yoshikawa; Toshiro Shirakawa; Akinobu Gotoh; Masafumi Matsuo; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

4.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

Authors:  A H Schinkel; U Mayer; E Wagenaar; C A Mol; L van Deemter; J J Smit; M A van der Valk; A C Voordouw; H Spits; O van Tellingen; J M Zijlmans; W E Fibbe; P Borst
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice.

Authors:  Manuela Pereira de Oliveira; Emmanuel Garcion; Nicolas Venisse; Jean-Pierre Benoit; William Couet; Jean-Christophe Olivier
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

6.  Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs.

Authors:  W T Klimecki; C W Taylor; W S Dalton
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

Review 7.  P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy.

Authors:  S Gupta
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

Review 8.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 9.  P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection.

Authors:  S Gupta; S Gollapudi
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.